ASX:TLXBiotechs
Can Telix (ASX:TLX) Turn Prostate Theranostics Partnerships Into An Edge Amid Legal Strains?
In December 2025, Telix Pharmaceuticals updated investors on the progression of its ProstACT Global Phase 3 trial for TLX591 in metastatic castration‑resistant prostate cancer and announced a new clinical collaboration with Varian to combine its prostate theranostics with external beam radiation therapy.
These developments come as Telix works to expand its prostate cancer platform globally while managing regulatory setbacks and class action lawsuits over alleged misstatements on clinical...